Tiopronin (Thiola) |
| رقم الكتالوجGC16209 |
Drug for cystinuria treatment
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1953-02-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Tiopronin (Thiola) is an inhibitor of cystine precipitation and excretion and used for the treatment of cystinuria [1].
Cystinuria is an inherited autosomal recessive disease that is characterized by the formation of cystine stones in the ureter, kidneys and bladder.
In seven cystinuric patients, tiopronin decreased the urinary supersaturation of cystine. The mean cystine capacity without tiopronin was 130.6 + 280.8, while the value during tiopronin use was 43.1 + 131.2 [1]. In 13 patients with cystinuria, the excretion of free cystine increased by 0.75 mg for each mM increase in urinary sodium, which suggested tubular reabsorption of cystine is in a sodium-dependent way [2]. In thirty-one patients with homozygous cystinuria, tiopronin reduced the urinary free cystine excretion by 0.15 mg in a dose-dependant way. Low doses of tiopronin increased urinary excretion of total cystine as well as the mixed disulfide [3]. In 13 patients with cystinuria, tiopronin decreased urinary cystine excretion from 901.48 mg to 488.60 mg [4].
References:
[1]. Dolin DJ, Asplin JR, Flagel L, et al. Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol, 2005, 19(3): 429-432.
[2]. Lindell A, Denneberg T, Edholm E, et al. The effect of sodium intake on cystinuria with and without tiopronin treatment. Nephron, 1995, 71(4): 407-415.
[3]. Lindell A, Denneberg T, Jeppsson JO. Urinary excretion of free cystine and the tiopronin-cysteine-mixed disulfide during long term tiopronin treatment of cystinuria. Nephron, 1995, 71(3): 328-342.
[4]. Koide T, Yoshioka T, Miyake O, et al. Long-term study of tiopronin in patients with cystinuria. Hinyokika Kiyo, 2003, 49(2): 115-120.
| Cas No. | 1953-02-2 | SDF | |
| Chemical Name | 2-(2-sulfanylpropanoylamino)acetic acid | ||
| Canonical SMILES | CC(C(=O)NCC(=O)O)S | ||
| Formula | C5H9NO3S | M.Wt | 163.19 |
| الذوبان | ≥ 6.8mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.1278 mL | 30.6391 mL | 61.2783 mL |
| 5 mM | 1.2256 mL | 6.1278 mL | 12.2557 mL |
| 10 mM | 612.8 μL | 3.0639 mL | 6.1278 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *